cilengitide has been researched along with dacarbazine in 18 studies
| Studies (cilengitide) | Trials (cilengitide) | Recent Studies (post-2010) (cilengitide) | Studies (dacarbazine) | Trials (dacarbazine) | Recent Studies (post-2010) (dacarbazine) |
|---|---|---|---|---|---|
| 194 | 29 | 133 | 7,556 | 1,463 | 3,429 |
| Protein | Taxonomy | cilengitide (IC50) | dacarbazine (IC50) |
|---|---|---|---|
| Matrix metalloproteinase-9 | Homo sapiens (human) | 0.556 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 14 (77.78) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Dorio, AS; Graziani, G; Lacal, PM; Muzi, A; Navarra, P; Ruffini, F; Tentori, L | 1 |
| Bokemeyer, C; Celik, I; Fiedler, W; Hauschild, J; Nippgen, J; Oliveira-Ferrer, L; Schuch, G | 1 |
| Adams, B; Maurer, GD; Stupp, R; Tabatabai, G; Tritschler, I; Weller, M; Wick, W | 1 |
| Desideri, S; Fisher, J; Grossman, SA; Nabors, LB; Piantadosi, S; Rosenfeld, M; Ye, X | 1 |
| Clement, PM; Dietrich, PY; Diserens, AC; Goldbrunner, R; Grabenbauer, GG; Hegi, ME; Hermisson, M; Hicking, C; Krueger, S; Neyns, B; Ochsenbein, AF; Pica, A; Picard, M; Pietsch, T; Schlegel, U; Simon, M; Stupp, R; Tonn, JC; Weller, M | 1 |
| Chamberlain, MC | 1 |
| Batchelor, T; Brem, S; Fisher, JD; Grossman, SA; Hegi, ME; Lesser, G; Mikkelsen, T; Nabors, LB; Olsen, J; Peereboom, D; Rosenfeld, MR; Ye, X | 1 |
| Caporello, P; Enrici, RM; Minniti, G; Scaringi, C | 1 |
| Classen, CF; Linnebacher, M; Mullins, CS; Schneider, B; Schubert, J | 1 |
| Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W | 1 |
| Adamska, K; Aldape, KD; Brandes, AA; Erridge, SC; Gorlia, T; Grujicic, D; Gupta, T; Hau, P; Hegi, ME; Herrlinger, U; Hicking, C; Hong, YK; Kim, CY; Kortmann, RD; Lhermitte, B; Markivskyy, A; McBain, C; Nabors, LB; Nam, DH; Perry, J; Picard, M; Pietsch, T; Rao, N; Reardon, DA; Schnell, O; Shen, CC; Steinbach, JP; Stupp, R; Taphoorn, MJ; Tarnawski, R; Thurzo, L; Tonn, JC; van den Bent, MJ; Weller, M; Weyerbrock, A; Wick, W; Wiegel, T | 1 |
| Chinot, OL | 1 |
| Ameratunga, MS; Grant, R; Khasraw, M; Pavlakis, N; Wheeler, H | 1 |
| Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V | 1 |
| Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H | 1 |
| Gramatzki, D; Roth, P; Seystahl, K; Weller, M | 1 |
| Ding, L; Gao, L; Lv, P; Qi, L; Wang, S; Wang, W; Xu, Y; Zhao, D; Zhong, Y | 1 |
| Alalami, H; Bannykh, S; Fan, X; Hu, J | 1 |
4 review(s) available for cilengitide and dacarbazine
| Article | Year |
|---|---|
Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Integrins; Mice; Rats; Signal Transduction; Snake Venoms; Temozolomide | 2012 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2014 |
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.
Topics: Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neovascularization, Pathologic; Snake Venoms; Temozolomide | 2016 |
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Cisplatin; Dacarbazine; Disease-Free Survival; Eflornithine; Glioma; Humans; Mitolactol; Network Meta-Analysis; Nimustine; Probability; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide; Treatment Outcome; Vincristine | 2016 |
6 trial(s) available for cilengitide and dacarbazine
| Article | Year |
|---|---|
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neurosurgical Procedures; Probability; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Risk Assessment; Snake Venoms; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Integrins; Male; Middle Aged; Snake Venoms; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2012 |
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Snake Venoms; Temozolomide; Treatment Outcome | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Promoter Regions, Genetic; Proportional Hazards Models; Reference Values; Snake Venoms; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Snake Venoms; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Procarbazine; Snake Venoms; Temozolomide; Treatment Failure; Tumor Suppressor Proteins; Young Adult | 2016 |
8 other study(ies) available for cilengitide and dacarbazine
| Article | Year |
|---|---|
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Synergism; Endothelial Cells; Integrins; Male; Melanoma; Mice; Mice, Inbred C57BL; Snake Venoms; Temozolomide | 2008 |
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
Topics: Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Cytoskeleton; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Endothelial Cells; Focal Adhesion Kinase 1; Glioblastoma; Humans; Oncogene Protein v-akt; Phosphorylation; Promoter Regions, Genetic; Snake Venoms; src-Family Kinases; Swine; Temozolomide; Tight Junctions; Tumor Suppressor Proteins | 2008 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; DNA Methylation; Drug Therapy, Combination; Gene Silencing; Glioma; Humans; Immunoblotting; In Vitro Techniques; Integrin alphaVbeta3; Mice; Neoplasm Invasiveness; NIH 3T3 Cells; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Vitronectin; Snake Venoms; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Benzodiazepines; Biomedical Research; Brain Neoplasms; Carboxymethylcellulose Sodium; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Interferon Inducers; Male; Middle Aged; Poly I-C; Polylysine; Receptors, AMPA; Snake Venoms; Survival Rate; Temozolomide; Treatment Outcome; United States; Young Adult | 2010 |
What role should cilengitide have in the treatment of glioblastoma?
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Snake Venoms; Temozolomide | 2010 |
Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Separation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Flow Cytometry; Glioblastoma; Humans; Inhibitory Concentration 50; Male; Middle Aged; Promoter Regions, Genetic; Snake Venoms; Temozolomide; Tumor Suppressor Proteins | 2013 |
Cilengitide in glioblastoma: when did it fail?
Topics: Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Snake Venoms; Temozolomide; Tumor Suppressor Proteins | 2014 |
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report.
Topics: Brain Neoplasms; Child; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Prognosis; Temozolomide | 2023 |